US deal activity saw an annual decrease in H1 of this year, but remains buoyant compared to pre-pandemic standards

Cash-rich pharma firms look set for a buying spree, as favorable biotech valuations and patent expirations incentivize dealmaking

At its core, the smart city is about people and improving the quality of our everyday lives.

Despite the absence of megadeals, M&A in the sector climbed from 2020 levels thanks in part to strong PE and SPAC activity

Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking.